相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study
Yoshiiku Kawakami et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
Hiromitsu Kumada et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature
Yuki Haga et al.
ONCOTARGET (2018)
Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection
Akira Doi et al.
HEPATOLOGY (2018)
Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1
Etsuko Iio et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Sofosbuvir-Velpatasvir With Ribavirin for 24 Weeks in Hepatitis C Virus Patients Previously Treated With a Direct-Acting Antiviral Regimen
Edward J. Gane et al.
HEPATOLOGY (2017)
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy
Goki Suda et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses
Tania M. Welzel et al.
JOURNAL OF HEPATOLOGY (2017)
Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure
Jun Itakura et al.
PLoS One (2016)
RETREATMENT OF PATIENTS WHO FAILED 8 OR 12 WEEKS OF LEDIPASVIR/SOFOSBUVIR- BASED REGIMENS WITH LEDIPASVIR/SOFOSBUVIR FOR 24 WEEKS
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
G. R. Foster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
J. J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy
Kazuaki Chayama et al.
VIRUSES-BASEL (2015)
Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
Hiromitsu Kumada et al.
HEPATOLOGY (2014)
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial
Masao Omata et al.
JOURNAL OF VIRAL HEPATITIS (2014)
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Changing Trends in Hepatitis C Infection over the Past 50 Years in Japan
Hobyung Chung et al.
INTERVIROLOGY (2010)
分享论文
